NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Eng J Med 2008;359:906–17 Disease progression in multiple […]
Category Archives: New medicines
NPC Archive Item: Alitretinoin for severe, refractory chronic hand eczema
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Ruzicka T, Lynde CW, Jemec GBE et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results […]
NPC Archive Item: Restrictions on the import of unlicensed melatonin products
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. MHRA drug procurement advice: Restrictions on the import of unlicensed melatonin products following marketing authorisation for Circadin®▼2mg tablets. 15th August 2008. A licensed melatonin product, (Circadin®▼ 2mg tablets) became […]
NPC Archive Item: Rivaroxaban for prevention of venous thromboembolism in patients undergoing total hip or knee replacement
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. N Engl J Med 2008; 358:2765-75 Kakkar AK, Brenner B, Dahl OE […]
NPC Archive Item: Modified-release melatonin launched for short-term treatment of primary insomnia
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr Med Res […]
NPC Archive Item: Cases of lung cancer reported in clinical trials of inhaled insulin (Exubera®▼)
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. http://www.fda.gov/medwatch/safety/2008/safety08.htm#exubera The FDA in America has issued a Dear Healthcare Professional letter regarding cases of lung cancer in clinical trials and during post-marketing surveillance in patients treated with Pfizer’s […]
NPC Archive Item: Vildagliptin launched in UK
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Vildagliptin▼(Galvus ®), a dipeptidyl peptidase type 4 (DPP-4) inhibitor and vildagliptin/metformin▼ (Eucreas®) have recently been launched in the UK. Vildagliptin is licensed for the treatment of type 2 diabetes […]
NPC Archive Item: Improving the reporting of conference/journal abstracts: new CONSORT guidance
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Hopewell S, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008 5: e20. doi:10.1371/journal.pmed.0050020 What is the background to […]
NPC Archive Item: Does agomelatine prevent relapse in patients with major depression?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Which study was this? A conference presentation of Goodwin G, Rouillon F and Emsley R. Long term efficacy of agomelatine, a novel antidepressant, in the prevention of relapse in […]
NPC Archive Item: Diabetes news – safety review of glitazones; inhaled insulin discontinued.
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Medicines and Healthcare products Regulatory Agency have announced the outcome of a Europe wide safety review of the glitazones. The review found a positive benefit-risk balance for both […]